Evaluating Different Doses of Orelabrutinib in MCL
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.
Mantle Cell Lymphoma
DRUG: Orelabrutinib High dose|DRUG: Orelabrutinib Low dose
Objective response rate（ORR）, Proportion of subjects with tumor response of Complete Response（CR） or Partial Response（PR） after treatment in total subjects., Through study completion, an average of 2 year
Complete Response Rate （CRR）, The proportion of subjects with tumor response of Complete Response（CR） after treatment in total subjects., Through study completion, an average of 2 year|Progression-Free Survival (PFS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first., Through study completion, an average of 2 year|Duration of Response (DoR), The time from documentation of objective response to the first occurrence of tumor progression or death due to any cause, whichever occurs first., Through study completion, an average of 2 year|Maximum concentration (Cmax,ss), Predose up to 24 hours postdose|Time to maximum concentration (Tmax), Predose up to 24 hours postdose|Area under the plasma concentration-time curve (AUC), Predose up to 24 hours postdose|Half-life (T1/2), Predose up to 24 hours postdose|Apparent clearance (CL/F), Predose up to 24 hours postdose|Adverse events（AEs）, Through study completion, an average of 2 year|Serious adverse events （SAEs）, Through study completion, an average of 2 year
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.